October 30.2020
AVATAMED and Macrogen sign MOU on joint business in personalized precision medicine services in cancer treatment
We are excited to collaborate with Macrogen, a global precision medicine Company with the best-in-class genetic platform, in offering our Precision Medicine services!
AVATAMED's drug screening technology (AVATASCAN), together with Macrogen's genetic platform, bring tremendous values to oncologists and their patients, as well as to the Pharmaceutical Industry.
For more information on the MOU, please refer to the attached Press Release.
From left: Macrogen Global Innovation Office SVP Dr. Bryan Sangjoon Hwang, Macrogen CEO Mr. Sukang Lee, AIMEDBIO CEO Prof. Do-Hyun Nam, Macrogen Chairman Dr. Jeong-Sun Seo, AVATAMED Application Scientist Ms. Miseol Son
From left: AVATAMED CEO Mr. Hong Boon Toh, Macrogen APAC CEO Dr. Kap-Seok Yang
October 30.2020
- Attachments
- AVATAMED-Macrogen_MOU_Press_Release_28102020.pdf